In a 1992 study in rats, the major finding was that intraperitoneal DSIP injection increased the concentration of substance P a neurotransmitter positively correlated with the regulation of anxiety and mood15 in the hypothalamus, suggesting to the researchers that the peptide sharply decreases the classical manifestations of stress.16 Earlier studies in humans, namely a series of five trials published in 1983, came to similar conclusions, with better relaxation and apparently improved tolerance against psychic stress reported by the subjects.17 Its possible that the improved stress and anxiety markers were consequent to DSIP-associated sleep enhancements.18 Substance use recovery A study from 1984 published in European Neurology describes DSIPs potential use as a treatment for alcohol and opiate use disorders
maintenance phase is the heavy draw 26 weeks 13 vials Standard Phase 2 duration 32 weeks 16 vials Phase 2 T2D study duration 68 weeks 30 vials REDEFINE 1 / REDEFINE 2 endpoint duration Peptide Vials (10 mg vial, 2.4 mg/week target) Each 10 mg vial covers about 4 weekly doses at 2.4 mg/week
BPC-157 first appeared in the early 1990s, when European researchers wondered why some stomach ulcers healed quickly while others didnt, Flynn McGuire, a physical medicine and rehabilitation resident at the University of Utah who is about to enter a sports medicine fellowship, tells Outside Run
Current Pharmaceutical Design , 2020 Injecting Far from the Injury Site (When Localized Healing Is Needed) If you're recovering from a joint, tendon, or ligament injury , injecting into the abdomen wont target the injured tissue as efficiently
